Korro Doses First Cohort in Phase 1/2 Trial for KRRO-121
KRRO sits 92% above its 52-week low of $5.204.
Summary
Korro Bio has dosed the first cohort in its Phase 1/2 ANCHOR trial for KRRO-121, its lead RNA editing candidate for hyperammonemia. This marks the company's transition to clinical-stage development, a key milestone for a $147M market cap biotech. The trial is enrolling healthy volunteers in Australia, with Part 1 SAD/MAD data expected to inform Part 2 dosing in UCD patients starting H1 2027. The company has $137.9M in cash, providing runway into 2H 2028, so this milestone is fully funded. While early-stage, the initiation of human dosing validates the OPERA platform and de-risks the program's timeline.
At the time of this announcement, KRRO was trading at $9.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.8M. The 52-week trading range was $5.20 to $55.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.